Volume 50, Issue 4, Pages (April 2009)

Slides:

Advertisements

Similar presentations

3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Volume 63, Issue 1, Pages (July 2015)

Volume 53, Issue 1, Pages (July 2010)

Volume 46, Issue 3, Pages (March 2007)

National Guidelines for Nursing Delegation

Inflammasomes in liver diseases

Volume 50, Issue 4, Pages (April 2009)

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis Wichit Srikureja,

Volume 67, Issue 2, Pages (August 2017)

Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”

Volume 61, Issue 6, Pages (December 2014)

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Volume 51, Issue 6, Pages (December 2009)

How to optimize the management of my HBeAg negative patients?

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 42, Issue 1, Pages (January 2005)

Immigration and viral hepatitis

Volume 123, Issue 6, Pages (December 2002)

Volume 66, Issue 1, Pages 1-4 (January 2017)

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results Bruno Roche, Didier Samuel Journal.

Living donor liver transplantation: is the hype over?

Volume 69, Issue 2, Pages (August 2018)

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

The place of downstaging for hepatocellular carcinoma

Volume 68, Issue 3, Pages (March 2018)

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

Volume 133, Issue 5, Pages (November 2007)

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence.

Volume 70, Issue 1, Pages (January 2019)

Chronic Hepatitis B: Current Testing Strategies

Volume 62, Issue 3, Pages (March 2015)

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Volume 68, Issue 4, Pages (April 2018)

EASL Clinical Practice Guidelines: Wilson’s disease

Volume 44, Issue 2, Pages (February 2006)

Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors

Volume 42, Issue 4, Pages (April 2005)

Volume 139, Issue 2, Pages (August 2010)

Volume 50, Issue 4, Pages (April 2009)

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Factors related to the chronicity and evolution of hepatitis C infection in patients co- infected by the human immunodeficiency virus R. Pérez-Cano, C.

Volume 67, Issue 5, Pages (November 2017)

Immigration and viral hepatitis

HCV targeting of patients with cirrhosis

Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin? Lawrence.

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Volume 63, Issue 1, Pages (July 2015)

Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection Isabelle Chemin,

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Volume 51, Issue 2, Pages (August 2009)

Chronic hepatitis B in children and adolescents

Volume 62, Issue 3, Pages (March 2015)

Volume 62, Issue 4, Pages (April 2015)

Volume 41, Issue 4, Pages (October 2004)

Liver transplantation in children

Pathogenesis of cholestatic hepatitis C

Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing Roongruedee Chaiteerakij,

Chimeric mouse model of hepatitis B virus infection

U.P. Neumann, M. Biermer, D. Eurich, P. Neuhaus, T. Berg

Volume 65, Issue 4, Pages (October 2016)

Thierry Gustot, Rajiv Jalan Journal of Hepatology

Emmet B. Keeffe, Douglas T

Presentation transcript:

Volume 50, Issue 4, Pages 644-647 (April 2009) Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice Pietro Lampertico Journal of Hepatology Volume 50, Issue 4, Pages 644-647 (April 2009) DOI: 10.1016/j.jhep.2009.01.007 Copyright © 2009 European Association for the Study of the Liver Terms and Conditions

Figure 1 Rates of partial virological responders (PVR), defined as patients with detectable HBV DNA by PCR assay at Week 24 for LMV and LDT and Week 48 for ADV, ETV, TDF. Viremia was quantified by Roche Cobas Amplicor PCR assay with a lower detection limit of 300copies/ml for LMV, LDT and ETV and by Roche Cobas Taq-Man PCR assay with a lower detection limit of 400copies/ml for TDF. Studies were not head-to-head. Baseline HBV DNA was expressed as log copies/ml. Journal of Hepatology 2009 50, 644-647DOI: (10.1016/j.jhep.2009.01.007) Copyright © 2009 European Association for the Study of the Liver Terms and Conditions